SG10201803877YA - Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment - Google Patents
Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatmentInfo
- Publication number
- SG10201803877YA SG10201803877YA SG10201803877YA SG10201803877YA SG10201803877YA SG 10201803877Y A SG10201803877Y A SG 10201803877YA SG 10201803877Y A SG10201803877Y A SG 10201803877YA SG 10201803877Y A SG10201803877Y A SG 10201803877YA SG 10201803877Y A SG10201803877Y A SG 10201803877YA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer treatment
- efficacy
- chemotherapy
- synbiotics
- responsiveness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907076P | 2013-11-21 | 2013-11-21 | |
| EP13306597.9A EP2876167A1 (en) | 2013-11-21 | 2013-11-21 | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201803877YA true SG10201803877YA (en) | 2018-06-28 |
Family
ID=49680948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201803877YA SG10201803877YA (en) | 2013-11-21 | 2014-11-21 | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10646521B2 (ja) |
| EP (2) | EP2876167A1 (ja) |
| JP (2) | JP6662775B2 (ja) |
| KR (1) | KR102464342B1 (ja) |
| CN (1) | CN106170557B (ja) |
| AU (1) | AU2014351348B2 (ja) |
| CA (1) | CA2931363C (ja) |
| DK (1) | DK3071709T3 (ja) |
| ES (1) | ES2764282T3 (ja) |
| IL (2) | IL245751B (ja) |
| PT (1) | PT3071709T (ja) |
| SG (1) | SG10201803877YA (ja) |
| WO (1) | WO2015075688A1 (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3291679T3 (pl) | 2015-05-06 | 2022-04-25 | Snipr Technologies Limited | Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty |
| EP3303401A4 (en) * | 2015-06-01 | 2018-12-26 | The University of Chicago | Treatment of cancer by manipulation of commensal microflora |
| EP3130680A1 (en) * | 2015-08-11 | 2017-02-15 | Universitat de Girona | Method for the detection, follow up and/or classification of intestinal diseases |
| EP4186927A1 (en) | 2015-10-21 | 2023-05-31 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| CN106011281B (zh) * | 2016-07-19 | 2019-04-23 | 浙江大学 | 肠道分节丝状菌鞭毛蛋白的检测方法 |
| BR112019005025A8 (pt) * | 2016-09-16 | 2023-03-21 | Ubiome Inc | Sistema e método para caracterizar um painel |
| JP2020500151A (ja) * | 2016-09-27 | 2020-01-09 | ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| US11684640B2 (en) | 2016-12-22 | 2023-06-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-based |
| WO2018145082A1 (en) * | 2017-02-06 | 2018-08-09 | New York University | Methods and compositions for treating and diagnosing pancreatic cancers |
| EP3378949A1 (en) * | 2017-03-22 | 2018-09-26 | Assistance Publique - Hôpitaux de Paris | Method for determining the potential efficacy of anticancer treatment |
| AR112328A1 (es) | 2017-07-05 | 2019-10-16 | Evelo Biosciences Inc | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis |
| BR112020002212A2 (pt) * | 2017-08-10 | 2020-07-28 | 4D Pharma Research Limited | composições compreendendo cepas bacterianas |
| EP3476396A1 (en) * | 2017-10-31 | 2019-05-01 | Institut Gustave Roussy | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same |
| EP3505177A1 (en) * | 2017-12-29 | 2019-07-03 | Institut Gustave Roussy | Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer |
| CN107904298A (zh) * | 2017-12-29 | 2018-04-13 | 苏州普瑞森基因科技有限公司 | 一种用于分析肠道微生物的试剂盒及其应用 |
| AU2019217041B2 (en) * | 2018-02-09 | 2022-09-15 | Keio University | Compositions and methods for the induction of CD8+ T-cells |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| EP3597202A1 (en) * | 2018-07-20 | 2020-01-22 | Maat Pharma | Fecal microbiota composition, for use in reducing treatment-induced inflammation |
| US11331269B2 (en) * | 2018-09-06 | 2022-05-17 | Massachusetts Institute Of Technology | Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment |
| EP3629023A1 (en) * | 2018-09-28 | 2020-04-01 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer |
| CN113166815A (zh) * | 2019-02-22 | 2021-07-23 | 深圳华大生命科学研究院 | 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| WO2020197362A1 (ko) * | 2019-03-28 | 2020-10-01 | 주식회사 천랩 | 패칼리박테리움속 미생물 및 이를 포함하는 항암 조성물 |
| CN111991427A (zh) * | 2019-05-07 | 2020-11-27 | 瑞微（深圳）生物科技有限公司 | 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用 |
| AU2020269080A1 (en) * | 2019-05-08 | 2021-12-16 | Megan BARNET | Cancer stratification and treatment based on inhibition of NOD-2 |
| AU2020373179A1 (en) * | 2019-11-01 | 2022-05-19 | Uti Limited Partnership | Harnessing the power of microbiota and metabolites for the treatment of cancer |
| WO2021102510A1 (en) * | 2019-11-26 | 2021-06-03 | South Australian Health And Medical Research Institute Limited | Methods and products for reducing side effects associated with use of immune agonist antibodies |
| CN116287355A (zh) * | 2023-05-12 | 2023-06-23 | 中国医学科学院北京协和医院 | 上消化道肿瘤化疗疗效及不良反应的肠道菌群预测模型 |
| CN117237952B (zh) * | 2023-11-15 | 2024-02-09 | 山东大学 | 基于免疫地形图的染色病理切片细胞分布标注方法及系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08295631A (ja) | 1995-02-27 | 1996-11-12 | Nichinichi Seiyaku Kk | 制癌増強剤 |
| JPH1029946A (ja) * | 1996-07-15 | 1998-02-03 | Nichinichi Seiyaku Kk | 液性免疫回復剤 |
| TW200904340A (en) | 2007-05-11 | 2009-02-01 | Mannatech Inc | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same |
| EP2687209A1 (en) | 2008-09-19 | 2014-01-22 | Nestec S.A. | Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| CN102215836B (zh) * | 2008-09-19 | 2015-07-08 | 雀巢产品技术援助有限公司 | 预防或减轻在抗癌治疗期间的骨髓瘫痪或中性白细胞减少症的营养支持 |
| JP5717116B2 (ja) * | 2008-12-22 | 2015-05-13 | 学校法人昭和大学 | 抗原特異的ヒトＴｈ１７細胞を調整する方法 |
| WO2011131472A1 (en) * | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
-
2013
- 2013-11-21 EP EP13306597.9A patent/EP2876167A1/en not_active Withdrawn
-
2014
- 2014-11-21 ES ES14812648T patent/ES2764282T3/es active Active
- 2014-11-21 US US15/038,073 patent/US10646521B2/en active Active
- 2014-11-21 SG SG10201803877YA patent/SG10201803877YA/en unknown
- 2014-11-21 EP EP14812648.5A patent/EP3071709B1/en active Active
- 2014-11-21 KR KR1020167016068A patent/KR102464342B1/ko active IP Right Grant
- 2014-11-21 WO PCT/IB2014/066249 patent/WO2015075688A1/en active Application Filing
- 2014-11-21 PT PT148126485T patent/PT3071709T/pt unknown
- 2014-11-21 CN CN201480063481.9A patent/CN106170557B/zh active Active
- 2014-11-21 JP JP2016533172A patent/JP6662775B2/ja active Active
- 2014-11-21 DK DK14812648.5T patent/DK3071709T3/da active
- 2014-11-21 AU AU2014351348A patent/AU2014351348B2/en active Active
- 2014-11-21 CA CA2931363A patent/CA2931363C/en active Active
-
2016
- 2016-05-19 IL IL245751A patent/IL245751B/en active IP Right Grant
-
2019
- 2019-08-05 IL IL268526A patent/IL268526B/en unknown
- 2019-12-09 JP JP2019221925A patent/JP2020050664A/ja active Pending
-
2020
- 2020-04-21 US US16/854,117 patent/US11344586B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6662775B2 (ja) | 2020-03-11 |
| US20160303172A1 (en) | 2016-10-20 |
| JP2020050664A (ja) | 2020-04-02 |
| US10646521B2 (en) | 2020-05-12 |
| CA2931363C (en) | 2023-07-18 |
| KR102464342B1 (ko) | 2022-11-08 |
| EP3071709B1 (en) | 2019-12-25 |
| PT3071709T (pt) | 2020-01-17 |
| EP2876167A1 (en) | 2015-05-27 |
| KR20160079122A (ko) | 2016-07-05 |
| IL268526B (en) | 2022-02-01 |
| US20200360449A1 (en) | 2020-11-19 |
| AU2014351348B2 (en) | 2020-12-03 |
| CA2931363A1 (en) | 2015-05-28 |
| CN106170557A (zh) | 2016-11-30 |
| IL268526A (en) | 2019-09-26 |
| IL245751B (en) | 2019-08-29 |
| EP3071709A1 (en) | 2016-09-28 |
| JP2016539119A (ja) | 2016-12-15 |
| DK3071709T3 (da) | 2020-03-16 |
| AU2014351348A1 (en) | 2016-06-09 |
| WO2015075688A1 (en) | 2015-05-28 |
| IL245751A0 (en) | 2016-07-31 |
| CN106170557B (zh) | 2020-08-21 |
| ES2764282T3 (es) | 2020-06-02 |
| US11344586B2 (en) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201803877YA (en) | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment | |
| MX2019009132A (es) | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. | |
| PH12015502401A1 (en) | Compositions and methods for enhancing microbial stability | |
| EA201990566A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EP3604535A3 (en) | Methods and compositions for weed control | |
| PH12015502216A1 (en) | Compositions and methods for improving the health of aquatic animals | |
| MX350773B (es) | Métodos y composiciones para el control de malezas. | |
| PH12016501512B1 (en) | Treatment for resistant acne | |
| WO2014145958A3 (en) | Network-based microbial compositions and methods | |
| WO2018115140A3 (en) | Virulence attenuated bacteria based protein delivery | |
| EA201792547A1 (ru) | Популяции бактерий для стимуляции состояния здоровья | |
| MX2015012334A (es) | Metodos y composiciones para el control de malezas. | |
| PH12016500207A1 (en) | Anti-infective compounds | |
| MX348495B (es) | Metodos y composiciones para el control de malezas. | |
| MX2021009001A (es) | Composiciones microbianas para alimentacion directa y sus metodos de uso. | |
| MX350774B (es) | Métodos y composiciones para el control de malezas. | |
| MX2013012165A (es) | Composicion y metodo para mejorar una respuesta inmune. | |
| EA202090683A3 (ru) | Способы и композиции для лечения рака | |
| MX2022013625A (es) | Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal. | |
| MX2020006191A (es) | Bacteriocinas terapeuticas. | |
| MY173304A (en) | Induction of immune tolerance using methotrexate | |
| MX2018001849A (es) | Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo. | |
| BR112018009753A2 (pt) | bactérias de virulência atenuada para o tratamento de tumores sólidos malignos | |
| MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
| MX2015008486A (es) | Composiciones y metodos para tratar infecciones bacterianas. |